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Abstract
Background In this study, a new safer and faster intra-
gastric balloon procedure was also employed to treat pre-
obese patients (body mass index (BMI)<30).
Methods From June 2006 to June 2009, 20 such patients
were submitted to the Silimed Gastric Balloon treatment, as
a part of a multidisciplinary program involving clinical,
psychological, andbehavioralapproaches.Forthe16patients
who had completed the 5–6-month treatment, the initial mean
weight and mean BMI were 74 kg and 27.5 kg/m
2,
respectively.
Results After the treatment, the mean weight and BMI
values decreased significantly to 65.9 kg and 24.5 kg/m
2,
respectively. There were only minor complications—nausea
and vomiting—with the exception of two cases of sponta-
neous deflation of the devices which were successfully
removed by gastric endoscopy.
Conclusions Thus, preliminary data suggest that this
new intragastric balloon procedure might also be a safe
and effective treatment for weight loss in pre-obese
patients.
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Introduction
Among the recently improved minimally invasive proce-
dures, silicone intragastric balloon has been a temporary
non-surgical option that can promote weight loss in obese
patients by partially filling their stomach and inducing a
sense of early satiety [1–4].
Recently, a new intragastric balloon technique with
technical improvements in the placement and removal
procedures, including the use of a new device known as
the Silimed Gastric Balloon (SGB), was developed which
demonstrated promising preliminary results in a group that
was mainly comprised of obese patients [5].
In the present study, the authors present the preliminary
use of this new improved procedure in the weight-loss
treatment of pre-obese patients (body mass index (BMI)
25.1–29.9) also. The preliminary results obtained are
presented and discussed.
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Patients
From June 2006 to June 2009, 20 patients with pre-treatment
BMI between 25.1 and 29.9 were submitted to treatment
with SGB. All of them failed to respond to previous clinical
treatment for weight loss. Their mean age was 37 (15–64)
years, mean initial weight was 74.6±9.8 (58.3–98.0) kg, and
mean BMI was 27.6±2.0 (21.6–29.9) kg/m².
Device
The SGB design specifications are based on certain require-
ments defined in the 1987 Tarpon Springs's International
Workshop for safety and efficiency of intragastric balloon
designs [6].
The SGB is supplied empty, and is delicately rolled up
inside a thin silicone sheath. This makes its placement and
positioninginthegastricfunduspossiblebyendoscopicroute.
The device consists of a smooth and transparent silicone shell
that acquires a round format when filled with saline solution.
The filling is done by a tube with a polytetrafluorethylene
needle at its extremity, which is connected to a self-sealing
valve attached to the device shell.
Initial Protocol
The pre-procedure was conducted by a multidisciplinary
team. The absolute contraindications were described in an
earlier study [5]. Free and informed consents were obtained
from each patient.
The SGB placement procedure was immediately preceded
by a diagnostic esophagogastroduodenoscopy to define the
gastric anatomy, verify any abnormalities contraindicative to
SGB placement, and aspirate the gastric content. After
removing the endoscope, the SGB was lubricated with
surgical lidocaine gel to initiate the insertion procedure.
Improved Placement and Removal Procedures [5]
Both the procedures were performed under usual sedation
of diagnostic endoscopy. During the placement procedure,
the extremity of SGB’s sheath was carefully anchored to the
endoscope extremity using a polypectomy snare (only the
extremity of the silicone sheath, and not of the shell, is tied
so that the shell of the device does not get damaged).
Subsequently, the SGB was smoothly inserted into the
stomach by traction under direct visual examination,
released by the polypectomy snare near the pylorus and
finally positioned in the gastric fundus observed by “J”
maneuver, followed by SGB traction by the introduction
catheter. In the gastric fundus, the SGB was filled with
saline solution (mean of 632 ml) through direct visual
examination and volumes of Iopamiron
® contrast (20 ml)
and 2% methylene blue (10 ml) were fixed with the
approximate final proportion of 65:2:1. The filling proce-
dure was continually monitored so that a better adequacy
of the SGB volume to the gastric capacity was achieved.
After the filling procedure, the SGB was visually inspected
for the detection of possible deflation or valve malfunctions
and confirmation of the correct positioning in the gastric
fundus. Antiemetics and antispasmodics were administered
orally or intravenously to control nausea, vomiting and pain
for 24–72 h. A proton pump inhibitor was prescribed for all
the patients during the 6-month treatment. The operational
mode of placement procedure is illustrated in an earlier
study [5].
The first part of the SGB removal procedure was the
positioning of a double silicon overtube previously lubri-
cated with surgical lidocaine gel in the patient's esophagus.
Under direct visual observation, a hole was made by a
specially developed catheter containing a needle (Scorpion)
in each SGB, and the catheter inserted to empty the SGB.
Each completely emptied SGB was captured by a poly-
pectomy snare, and also pulled until part of the SGB was
held in the overtube. For the very flat balloon a double-
hook endoscopic forceps was used to bring the balloon
partially inside the esophagus, grasped by the polypectomy
snare, allowing the simultaneous removal of the balloon
along with the whole endoscopic apparatus (Fig. 1).
Statistics
To confirm the normal distribution of the efficiency
variables, the Shapiro–Wilk’s test for normality was used.
The test t for paired observations under the significance of
Fig. 1 Final stage of the SGB removal procedure, when the
completely deflated balloon is removed along with the whole
endoscopic apparatus
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the proposed treatment. The descriptive statistics values
were presented as mean ± standard deviation.
Results
In all the cases, SGBs were successfully placed and removed
under usual sedation of diagnostic endoscopy. All but two of
the 16 patients who had completed the 5–6-month treatment
demonstrated good weight loss at the end of the treatment.
The mean final weight was 65.9±9.4 (49.3–81.9) kg and the
mean final BMI was 24.5±2.6 (21.6–28.5) kg/m² (Fig. 2).
These preliminary results were statistically significant.
The only initial complications were episodes of nausea,
vomiting, and epigastric pain. Epigastric pain and severe
vomiting occurred in two patients, leading to early
termination of the treatment. There was no occurrence of
late complications, such as severe esophagitis, peptic ulcer,
and gastric perforation or erosion. The only major compli-
cations were two cases of spontaneous deflation of the
devices which were removed uneventfully by office
endoscopy.
Discussion
The use of an intragastric device to control weight in obese
patients was first described in 1982 [7]. However, the first
gastric balloons did not yield the expected results of weight
loss, mainly owing to the technical aspects of the devices’
design such as the filling of the devices with air and the
presence of a low-resistant balloon shell with rough surface.
In 1999, a new silicone gastric balloon filled with saline
solution was presented and recommended for 6-months
usage [8], and ever since, significant results with this device
have been obtained [1–4]. Recently, a series of technical
improvements in the intragastric balloon procedure using a
new balloon—SGB—was proposed, and encouraging pre-
liminary results of safety and efficiency in obese patients
were obtained [5] .B a s e do nt h i si n i t i a ls u c c e s s ,t h e
objective of the present study was to use the new SGB
technique in the weight-loss treatment of pre-obese patients.
In this series, the improved procedures of placement and
removal of the new saline solution-filled balloon also proved
to be safer and faster: all the SGBs were successfully placed
and removed by office endoscopy, with no intercurrences
during the procedures. Also, these procedures were perfectly
feasible under the usual sedation of diagnostic endoscopy in
ambulatory level, thus avoiding the risks and costs of general
anesthesia and operation room. The other main innovations of
this new technique include the simplicity and shortened
duration of the placement and removal procedures, decrease
of pharynx irritation during the placement procedure, better
radiopaque visualization of the device along the treatment,
and minimal risk of damage to the esophagus or tracheal
aspiration or device loss in the digestive tract during the
removal procedure [5].
The careful anchoring of the extremity of the SGB’s
sheath to the extremity of the endoscope made the
placement of the device by traction possible, and appeared
to be simpler and more effective than the placement by a
tube that pushes the device without visual monitoring, as
occurs in the usual placement procedure of modern intra-
gastric balloons. The direct visualization enabled the fast
positioning of the SGB in the gastric fundus, thereby
reducing the excessive manipulation of the endoscope and
the consequent risk of damage to the pharynx.
Although SGB has a radiopaque mark around the valve,
the use of Iopamiron
® in the filling solution of the device
contributes to obtaining more clearly defined images on the
correct placement of the balloon, whenever necessary.
Fig. 2 a, b Boxplots showing the means and dispersions of the initial
and final data of the 12 patients who had completed the 6-month
treatment with SGB
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followed by the joining of SGB directly to the overtube,
and the simultaneous removal of the whole endoscopic
apparatus, constituted a very safe and effective removal
procedure in all cases, as occurred in the initial series [5].
Even in the high pressure area of the esophagus, at the level
of the cricopharyngeal muscle, the overtube containing the
SGB passed through easily, thus minimizing the risk of
damage to the esophagus or device loss in the digestive
tract. The use of the overtube practically annulled the risk
of tracheal aspiration of saline solution or food residues,
thus making the procedure of tracheal intubation unneces-
sary for controlling these risks. Furthermore, the shortened
removal time of SGB resulted in using fewer antispas-
modics and decreasing thereby the patient’s discomfort,
mainly due to lower transparietal stimulation by the
endoscopic apparatus and consequent reduction of the
spams of the cardia and the esophagus.
In this series, there was no occurrence of any serious
complications, such as erosion or peptic ulcer, except for two
cases of spontaneous deflation of the balloon (one occurred
after 6 months of treatment). In both cases, the deflated
devices were successfully removed by gastric endoscopy.
All but two of the 16 pre-obese patients who completed
the treatment with SGB lost weight significantly, the mean
loss being 8.1±4.7 kg. The use of t test for paired
observations under significance of 0.01 showed that these
preliminary results of weight loss in this group of patients
were significant. However, the possibility of placebo effect
or weight loss due only to behavioral changes cannot be
excluded. Nonetheless, two aspects that reinforce the
effectiveness of SGB merit emphasis: (1) the recent
publication of Genco et al. [4] showing that the modern
concept of saline solution-filled intragastric balloon in the
weight-loss treatment of obese patients is more effective
than the sham procedure associated with restricted diet and
(2) the failure history of the patients of the present series to
previous clinical treatments for weight loss.
Once the preliminary mean weight loss achieved in the
present series is more expressive than those presented by
randomized controlled studies using orlistat, sibutramine,
and rimonabant to reduce weight in pre-obese patients [9,
10], we think that the SGB technique may act as an
alternative to weight-loss treatment with drugs for these
patients. Further analysis of a more representative sample
will be necessary to test this hypothesis.
Thereby, these early results reinforce the concept of
efficacy and safety of the SGB treatment, and suggest a
favorable balance between benefits and risks even in pre-
obese patients.
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